 The Armacran variant of the SARS-CoV-2 virus has rapidly become the most predominant variant globally, leading to the emergence of multiple subvariants. Two of these subvariants, BQ.1 and XBB, have demonstrated increased transmissibility and immunovasion capabilities, making them a major public health threat. These subvariants are able to evade neutralizing antibodies from vaccinated or convalescent COVID-19 patients and therapeutic monoclonal antibodies, allowing them to spread more easily. To combat this, researchers have identified the F-86P mutation in XBB.1.5, which is responsible for its enhanced transmissibility and immunovasion abilities. Additionally, researchers have developed strategies to prevent the spread of BQ.1 and XBB sublineages, such as using MABS to target the F-86P mutation and developing vaccine adjuvants to enhance the efficacy of vaccination. This article was authored by Danny Aoe, Kazumai He, Waikihong, and others.